Research programme: parathyroid hormone receptor antagonist therapeutics - Crinetics Pharmaceuticals
Latest Information Update: 17 Sep 2026
At a glance
- Originator Crinetics Pharmaceuticals
- Class Antihypercalcaemics; Small molecules
- Mechanism of Action Parathyroid hormone receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypercalcaemia; Thyrotoxicosis
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for preclinical development in Hypercalcaemia in USA (PO)
- 28 Apr 2026 No recent reports of development identified for preclinical development in Thyrotoxicosis in USA (PO)
- 21 Jun 2023 Pharmacodynamics data from a preclinical trial in Hypercalcaemia presented at the Endocrine Society’s annual meeting (ENDO-2023)